rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children with diabetes mellitus. The FDA approved 3 mL single-patient-use prefilled pen and 10 mL ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Merilog will be provided by prefilled pen in a 3 mL dose or in ... for those with commercial insurance. NovoLog and Novo Nordisk’s other rapid-acting insulin follow-on Fiasp are among the ...

NovoLog is also available in pen injector formats. Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris ...

The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. Merilog is a ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Merilog is the first rapid-acting biosimilar human analog insulin approved by ... 3 mL single-patient-use prefilled pen and a 10 mL multiple-dose vial. Like Novolog, Merilog should be given ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

Like Novolog, Merilog should be administered within ... According to MSF, data published in JAMA Network Open shows that insulin pens could be produced for as little as $0.94 per unit and remain ...